Ningbo Xijian Pharmaceutical Technology Co Ltd

Primary objective: To evaluate the effectiveness of EG017 tablets in the treatment of stress urinary incontinence (SUI) in postmenopausal middle-aged and elderly women, using placebo as a control. Secondary objectives: Applicable to the treatment period: 1. Using placebo as a control, at multiple efficacy evaluation time points, and using multiple efficacy evaluation indicators (except the primary study endpoint), to evaluate the efficacy of EG017 tablets in the treatment of SUI in postmenopausal middle-aged and elderly women; 2. To evaluate the pharmacokinetics (PK) of EG017 tablets in postmenopausal middle-aged and elderly women with SUI; 3. To evaluate the safety of EG017 tablets in the treatment of postmenopausal middle-aged and elderly women with SUI.

The primary objective was to evaluate the safety of multiple oral administration of 12 mg EG017 tablets in the fasting state in healthy middle-aged and elderly postmenopausal female subjects. The secondary objective was to evaluate the pharmacokinetic (PK) characteristics of multiple oral administration of 12 mg EG017 tablets in the fasting state in healthy middle-aged and elderly postmenopausal female subjects and to identify the metabolites of EG017 tablets in the blood of healthy middle-aged and elderly postmenopausal female subjects.

Main purpose To preliminarily evaluate the efficacy and safety of EG017 tablets in the treatment of stress urinary incontinence in postmenopausal middle-aged and elderly women with placebo as a control. Secondary purpose 1. To explore the optimal safe and effective dose of EG017 tablets in the treatment of stress urinary incontinence in postmenopausal middle-aged and elderly women; 2. To explore the changes in body fat ratio (weight loss) of postmenopausal middle-aged and elderly women treated with EG017 tablets.